Mogrify

Mogrify appoints Dr Jonathan Appleby as chief scientific officer

Strategic hire bolsters executive leadership team as company progresses multiple therapeutic programmes toward and into clinical development 15 July 2024 – Cambridge, UK – Mogrify, a regenerative medicine company developing a novel class of in vivo reprogramming therapies for diseases with high unmet clinical need, announces the appointment of Dr Jonathan Appleby as chief scientific...

Mogrify extends Series A financing to $46m USD

Additional close of $10m USD brings total raised in Series A to $46m USD Funding co-led by Astellas Venture Management and Parkwalk Advisors with participation from other internal investors. Funding will support advancement of Mogrify’s dedicated pipeline of in vivo reprogramming therapies through pre-clinical translation, continued platform optimization, and facilitation of new and existing biopharma...

Mogrify and Astellas Announce Collaboration to Conduct Research on In Vivo Regenerative Medicine Approaches to Address Sensorineural Hearing Loss

Cambridge, UK, Tokyo, Japan, 05 July 2022: Mogrify Limited (CEO: Darrin M. Disley, Ph.D., 'Mogrify'), a biopharmaceutical company transforming the lives of patients through a novel class of in vivo reprogramming therapies, and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., 'Astellas'), a leader in regenerative medicine, today announced that they have...
25 Cambridge Science Park Milton Rd, Milton, Cambridge CB4 0FW

+ 44 (0)1223 734154 Get In Contact Now